A nasal vaccine for COVID-19—based on technology developed at Washington University in St. Louis—is poised to enter a phase 1 ...

US biotech Novavax has begun a phase 1 study of its coronavirus vaccine ... The company has plans to produce up to 100 million vaccine doses by the end of this year, scaled up to more than ...

The CDC ACIP recommends 2 doses of the 2024-2025 COVID-19 vaccine for those age 65+ years and 2 or more doses for immunocompromised individuals.

and deliver 100 million doses of NVX‑CoV2373, Novavax’ COVID-19 vaccine candidate, as early as late 2020. Novavax undertook this herculean task with admirable pluck, albeit not without fumbles ...

NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that doses of the Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705 ...

After two years characterized by layoffs, pipeline reorganizations, FDA delays and clinical holds, Novavax CEO John Jacobs ...

The NHS spring booster campaign will offer jabs to limited groups of vulnerable patients from 1 April. More than 9.7 million ...

What Else: Novavax stands out for its non-mRNA approach to combating infectious diseases. The company's flagship product, Nuvaxovid, a COVID-19 vaccine ... has a 52-week high of $23.86 and ...

Nearly two years into the COVID-19 pandemic, Canada is ramping up its vaccine program in an effort to deliver booster doses to eligible ... Sanofi-GlaxoSmithKline, Novavax and J&J.

India has bought 1.6 billion doses of Covid-19 vaccines ... of the Oxford University-AstraZeneca vaccine candidate, one billion from the American company Novavax and 100 million doses of the ...

The Company has achieved a milestone associated with its Phase 2/3 clinical trial for its COVID-19 vaccine in children, triggering the first $50 million milestone payment from Sanofi. Novavax (NVAX) ...